Boron neutron capture therapy for cancer. Realities and prospects

Cancer

Volumn 70, Issue 12, 1992, Pages 2995-3007

  Barfh, Rolf F ^a   Soloway, Albert H ^a   Fairchild, Ralph G ^b   Brugger, Robert M ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b Associated Universities Inc   (United States)

Author keywords

boron neutron capture therapy; cancer

Indexed keywords

BORON 10; MONOCLONAL ANTIBODY;

BRAIN CANCER; CANCER RADIOTHERAPY; GLIOBLASTOMA; HUMAN; MELANOMA; MICRODOSIMETRY; NEUTRON RADIATION; NUCLEAR REACTOR; PRIORITY JOURNAL; RADIATION DOSE; RADIOBIOLOGY; REVIEW;

BORON NEUTRON CAPTURE THERAPY; HUMAN; NEOPLASMS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0026464493     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19921215)70:12<2995::AID-CNCR2820701243>3.0.CO;2-#     Document Type: Article

References (120)

1. Photodynamic therapy: new approaches
2. Activation of prodrugs by antibody‐enzyme conjugates: a new approach to cancer therapy
3. Halogenated pyrimidines as radio‐sensitizers for high grade glioma: revisited
4. Boron neutron capture therapy of cancer
5. Intermediate energy neutron beams from the MURR
6. Installation and testing of an optimized epithermal neutron beam at the Brookhaven Medical Research Reactor (BMRR)
7. A study of low energy proton accelerators for neutron capture therapy
8. Boron neutron capture enhancement of 252Cf brachytherapy
9. Neutron capture therapy
10. 7Li reaction in HeLa cells
11. Sublethal and potentially lethal damage repair on thermal neutron capture therapy
12. Radiation biology of malignant melanoma
13. Radiation therapy for neoplasms of the brain
14. 10B‐neutron capture therapy for early skin reaction in the hamster
15. 7Li reaction on cultured B‐16 melanoma cells
16. Determination of boron in biological tissues by inductively coupled plasma atomic emission spectrometry
17. Determination of boron in tissues and cells using direct‐current plasma atomic emission spectroscopy
18. Quantitative imaging of boron, calcium, magnesium, potassium, and sodium distributions in cultured cells with ion microscopy
19. Electron spectroscopic imaging for high resolution immunocytochemistry: use of boronated protein A
20. Microdosimetry for boron neutron capture therapy
21. Energy deposition in small ellipsoidal volumes by high‐LET particles: application to thermal neutron dosimetry
22. 7Li reaction in cells and tissue and its implication for boron neutron capture therapy
23. The possible use of neutron‐capture isotopes such as boron‐10 in the treatment of neoplasms: II. computation of the radiation energy and estimates of effects in normal and neoplastic brain
24. Boron neutron capture therapy of cerebral gliomas: II. utilization of the blood‐brain barrier and tumor‐specific antigens for the selective concentrations of boron in gliomas
25. Boron compounds and boronated antibodies for neutron capture therapy
26. Proposed clinical approach to BNCT
27. 7Li reaction
28. 7Li reaction on the skin of man
29. The dose‐rate factor in radiation biology
30. Some thoughts on tolerance, dose, and fractionation in boron neutron capture therapy
31. Evaluation of boron compounds for use in neutron capture therapy of brain tumors: I. Animal investigations
32. Boron‐slow neutron capture therapy of gliomas
33. Boron compounds in cancer therapy
34. A history of boron neutron capture therapy of brain tumours
35. Neuropathologic study of fourteen cases of malignant brain tumor treated by boron‐10 slow neutron capture radiation
36. Effect of neutron capture irradiation upon malignant brain tumors in mice
37. Penetration of brain and brain tumor: VII. tumor‐binding sulfhydryl boron compounds
38. A revised boron‐neutron capture therapy for malignant brain tumors: II. interim clinical result with the patients excluding previous treatments
39. Clinical experience of boron‐neutron capture therapy for gliomas: a comparison with conventional chemo‐immuno‐radio‐therapy
40. Boron‐neutron capture therapy for tumors
41. 10B‐paraborono‐phenylalanine HCI to malignant melanoma for thermal neutron capture therapy
42. 10B‐para‐boronophenylalanine in thermal neutron capture therapy of malignant melanoma: in vivo radiobiological evaluation
43. 10Bcompound
44. Treatment of malignant melanoma by selective thermal neutron capture therapy using melanoma‐seeking compound
45. Synthesis, antineoplastic activity and biodistribution of boron analogues of amino acids and related compounds
46. L‐O‐Carboranylalanine, a boron analogue of phenylalanine
47. Analytical calculation of boron‐10 dosage in cell nucleus for neutron capture therapy
48. Synthesis and properties of boron and silicon substituted uracil or 2′ ‐deoxyuridine
49. Boron‐10 carriers for NCT. A new synthetic method via condensation with aldehydes having boronic moiety
50. Synthesis of a carboranyl nucleoside for potential use in neutron capture therapy of cancer
51. Synthesis and in vitro evaluation of boronated uridine and glucose derivatives for boron neutron capture therapy
52. Direct intratumoral injection of 2′ ‐O‐ (o‐carboran‐l‐y1‐methyl) uridine (CBU‐Y), a potential delivery agent for boron neutron capture therapy (BNCT) [abstract]
53. Cellular and biochemical studies on T‐O‐ (o‐carboran‐l‐yl‐methyl) uridine (CBU‐2), a delivery agent for boron neutron capture therapy (BNCT) [abstract]
54. Boronated compounds for neutron capture therapy
55. 10B‐chlorpromazine compound
56. Boron‐containing thiouracil derivatives for neutron‐capture therapy of melanoma
57. Uptake of a nido‐carboranylporphyrine by human glioma xenografts in athymic nude mice and by syngeneic ovarian carcinomas in immunocompetent mice
58. In vitro determination of uptake, retention, distribution, biological efficacy and toxicity of boronated compounds for neutron capture therapy: a comparison of porphyrins with sulfhydryl boron hydrides
59. Synthesis and in vivo studies of a carboranyl porphyrin
60. Boronated porphyrins in NCT: results with a new potent tumor localizer
61. Biological efficacy of boronated low‐density lipoprotein for boron neutron capture therapy as measured in cell culture
62. Liposomal delivery of boron for BNCT
63. Protein‐binding polyhedral boranes 3
64. Preparation of tumor‐specific boron compounds: I. In vitro studies using boron labeled antibodies and elemental boron as neutron targets
65. Continuous cultures of fused cells secreting antibody of predefined specificity
66. Neutron capture using boronated monoclonal antibody directed against tumor‐associated antigens
67. Neutron capture therapy of human cancer: in vivo results on tumor preparation of boron‐labeled antibodies to carcinoembryonic antigen
68. Neutron capture therapy of human cancer: in vivo results on tumor localization of boron‐10‐labeled antibodies to carcinoembryonic antigen in the GW‐39 tumor model system
69. Dicesium N‐succinimidyl 3‐ (undecahydro‐closo‐dodecaboranyl‐dithio)propionate, a novel heterobifunctional boronating agent
70. Delivery of boron‐10 for neutron capture therapy by means of polyclonal and monoclonal antibodies: progress and problems
71. Boron containing immuno‐conjugates for neutron capture therapy of cancer and for immunocytochemistry
72. Boron neutron capture therapy: linkage of a boronated macromolecule to monoclonal antibodies directed against tumor associated antigens
73. Conjugation, purification and characterization of boronated monoclonal antibodies for use in neutron capture therapy
74. Novel carboranyl amino acids and peptides: reagents for antibody modification and subsequent neutron‐capture studies
75. Starburst dendrimers: III. the importance of branch junction symmetry in the development of topological shell molecules
76. Delivery of boron‐10 for neutron capture therapy by means of monoclonal antibody: starburst dendrimerimmunoconjugates
77. Optimization of fast neutron spectra available for neutron capture therapy
78. 10B molecule‐melanoma cell interaction from in vitro to first clinical trial
79. Research on neutron beam design for BNCT at the Musashi reactor
80. Intermediate energy neutron beams for neutron capture therapy: a progress report
81. Optimization of an epithermal beam for NCT at the Brookhaven Medical Research Reactor (BMRR)
82. Rapporteur's report
83. Neutron capture therapy beams at the MIT research reactor
84. An epithermal neutron beam for neutron capture therapy at the Missouri University Research Reactor
85. Reactor moderated intermediate energy neutron beams for neutron capture therapy
86. Treatment planning methods with Cf‐252 at the University of Kentucky
87. The possible use of a spallation neutron source for neutron capture therapy with epithermal neutrons
88. A versatile, new accelerator design for boron neutron capture therapy: accelerator design and neutron energy considerations
89. An experimental study of the moderator assembly for a low‐energy proton accelerator neutron irradiation facility for BNCT
90. A neutronic study of an accelerator‐based irradiation facility for boron neutron capture therapy
91. Workshop summary of moderators' reports
92. Progress towards boron neutron capture therapy at the high flux reactor Petten
93. Neutron capture therapy with boron in the treatment of glioblastoma multiforme
94. Pathological study of eight patients with glioblastoma multiforme treated by neutron‐capture therapy using boron 10
95. The possible use of neutron‐capturing isotopes such as boron‐10 in the treatment of neoplasms: I. intracranial tumors
96. Clinical results of boron neutron capture therapy
97. Biodistribution of boron sulfhydral (BSH) in patients with intracranial tumors
98. The Petten BNCT project
99. Proposed patient selection criteria and follow‐up
100. Advances in the control of human cutaneous primary and metastatic melanoma by thermal neutron capture therapy
101. Boron neutron capture therapy of a murine melanoma
102. Metastatic patterns in autopsy cases of cutaneous melanoma
103. Relapse in the central nervous system in melanoma patients successfully treated with biomodulators
104. A rat model for the treatment of melanoma metastatic to the brain by means of neutron capture therapy
105. Experimental boron neutron capture therapy for melanoma: systemic delivery of boron to melanotic and amelanotic melanoma
106. Boron neutron capture therapy of anterior chamber melanoma with p‐boronophenylalanine
107. Three dimensional radiation dose distribution analysis for boron neutron capture therapy
108. Boron‐11 imaging with a three‐dimensional reconstruction method
109. Use of organoboranes in modern medical imaging
110. Phantom experiment in calculation for in vivo boron analysis by prompt gamma ray spectroscopy
111. Mechanism of tumor destruction following photodynamic therapy with hematoporphyrin derivative, chlorin and phthalocyanine